AI-generated analysis. Always verify with the original filing.
PDS Biotechnology Corporation reported full year 2025 net loss of $34.5 million and cash balance of $26.7 million as of December 31, 2025, alongside VERSATILE-003 Phase 3 trial amendment incorporating PFS as interim endpoint.
Event Type
Disclosure
Mandatory
Variant
8-K
| Results of Operation and Financial Condition. | |---|---| On March 30, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing a
| Financial Statements and Exhibits. | |---|---| (d) Exhibits. | Exhibit Number | | Description | |---|---|---| | | | | | 99.1 | | Press Release dated March 30,
| Metric | Value | Basis |
|---|---|---|
| Net Loss | $-34.50 | GAAP |
| Net Loss per Share, Basic and Diluted | $-0.74 | GAAP |
| Research and Development Expenses | $19.00 | GAAP |
| General and Administrative Expenses | $12.50 | GAAP |
| Total Operating Expenses | $31.50 | GAAP |